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Background: Implant-related osteomyelitis (IRO) is recently controlled with local antibiotic delivery systems to
overcome conventional therapy disadvantages. In vivo evaluation of such systems is however too little.
Questions/purposes: We asked whether vancomycin (V)-containing poly-l-lactic acid/β-tricalcium phosphate
(PLLA/β-TCP) composites control experimental IRO and promote bone healing in vivo.
Methods: Fifty-six rats were distributed to five groups in this longitudinal controlled study. Experimental IRO was
established at tibiae by injecting methicillin-resistant Staphylococcus aureus (MRSA) suspensions with titanium particles
in 32 rats. Vancomycin-free PLLA/β-TCP composites were implanted into the normal and infected tibiae, whereas
V-PLLA/β-TCP composites and coated (C)-V-PLLA/β-TCP composites were implanted into IRO sites. Sham-operated tibiae
established the control group. Radiological and histological scores were quantified with microbiological findings on
weeks 1 and 6.
Results: IRO is resolved in the CV- and the V-PLLA/β-TCP groups but not in the PLLA/β-TCP group. MRSA was not
isolated in the CV- and the V-PLLA/β-TCP groups at all times whereas the bacteria were present in the PLLA/β-TCP
group. Radiological signs secondary to infection are improved from 10.9 ± 0.9 to 3.0 ± 0.3 in the V-PLLA/β-TCP group
but remained constant in the PLLA/β-TCP group. Histology scores are improved from 24.7 ± 6.5 to 17.6 ± 4.8 and from
27.6 ± 7.9 to 32.4 ± 8.9 in the CV-PLLA/β-TCP and the V-PLLA/β-TCP groups, respectively. New bone was formed in all
the PLLA/β-TCP group at weeks 1 and 6.
Conclusions: CV- and V-PLLA/β-TCP composites controlled experimental IRO and promoted bone healing.
Clinical relevance: CV- and V-PLLA/β-TCP composites have the potential of controlling experimental IRO and promoting
bone healing.
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Implant-related osteomyelitis (IRO) [1] is a complex
bone infection that requires the surgical removal of se-
quester or implant [2] followed with the debridement
of the infected tissues [3] and high dosage antibiotic
regimen for 6 weeks [4]. Staphylococcus aureus is the
main causative organism for osteomyelitis [5]. It can
form a biofilm, an extracellular polymeric matrix, in
which cells can communicate and protect themselves
from antibacterial agents [6]. Methicillin-resistant S.
aureus (MRSA) is a strain of S. aureus, which mainly* Correspondence: feza.korkusuz@hacettepe.edu.tr
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unless otherwise stated.caused nosocomial bone infections [7]. Vancomycin is a
frequently used antibiotic against infections caused by
MRSA [8]. Local antibiotic delivery systems [9,10] are
proposed to control IRO safely and efficiently as paren-
teral administration of high doses of vancomycin for
long durations may lead to some effects [11].
Although various degradable polymers [12,13] and β-
TCP [14] were used to release antibiotics, in vivo evalu-
ation of these systems was rarely [15,16] undertaken. A
vancomycin-containing poly-l-lactic acid/β-tricalcium
phosphate (V-PLLA/β-TCP) composite was recently de-
veloped and characterized for this reason [17]. PLLA
slowed vancomycin release and β-TCP aided mesenchy-
mal stem and Saos-2 bone cells attachment, prolifera-
tion, and differentiation in vitro [17]. This compositeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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91.9% of the vancomycin released on days 1 and 42, re-
spectively. CV- and V-PLLA/β-TCP composites further-
more generated the extracellular bone matrix and attained
mineralization that may point out tissue regeneration [17].
In this study, we asked whether CV- and V-PLLA/β-TCP
composites controlled experimental IRO and promoted
bone healing in vivo.
Materials and methods
A longitudinal controlled study in rat tibiae was designed
after ethical committee approval. Independent variables
were groups (n =5) and time (n =2) and dependent vari-
ables were radiological, histological, and microbiological
scores. Free online software was used to calculate the sam-
ple size of the study. The power 1-beta and type I error
rate alpha were set to 0.8% and 5%, respectively. Power
analysis with 56 rats revealed 0.81% confidence; therefore,
minimum 10 rats were assigned into one of the five ex-
perimental groups. In the control group, the tibiae of the
rats underwent sham operation without IRO establish-
ment (n =12). PLLA/β-TCP composites were implanted
into the non-infected tibiae in the second group (n =12).
The PLLA/β-TCP, the V-PLLA/β-TCP, and the CV-
PLLA/β-TCP composites were implanted into the IRO-
established tibiae (n =12, n =10, and n =10), respectively,
in the last three groups (Figure 1). We examined the
groups after 1 and 6 weeks and quantified their radio-
logical, histological, and microbiological findings.
Composites were developed and characterized as pre-
viously described [17]. Briefly, 8% vancomycin solution
was prepared with 920 mg deionized water. This solu-
tion was mixed with 720 mg β-TCP and dried at 37°C
for 12 h. The final mixture was added to 3% PLLA solu-
tion that contained 2.67 g chloroform and molded toFigure 1 The experimental design and study groups are shown. n = nobtain a spherical shape. MRSA (strain: ATCC 2592)
was obtained from the microbiological collection of
Ankara Numune Hospital Microbiology Laboratory. We
used 3-month-old male Sprague–Dawley rats weighing
300–350 g housed in a temperature-controlled room
(22°C–24°C) with 12-h light and 12-h dark cycles. Rats
were given free access to water and food without antibi-
otics for 24 h a day. They were anesthetized by intraperi-
toneal 0.2 mL ketamine chloride (Ketasol 10%, Richter-
Pharma, Wels, Austria) and 0.1 mL xylazine (Alfazyne
2%, Alfasan, Woerden, the Netherlands) injection. The
left hind limb was shaved and cleaned with iodine solution
(Polyod, Drogsan, Ankara, Turkey). The proximal anterior
cortex of the tibia was exposed and drilled through with a
3.2-mm burr (Dremel, Gerlingen, Germany). We irri-
gated the burr hole with 0.09% sodium chloride solu-
tion (Eczacıbaşı-Baxter, Istanbul, Turkey) and injected a
0.1 mL MRSA suspension (1 × 106 CFU/cm3) into the
intramedullary cavity with approximately 200 1.0 × 1.0-
mm titanium particles to establish IRO in the last three
groups. The burr hole was closed with bone wax (Ethicon,
Johnson & Johnson, New Brunswick, NJ, USA) to pre-
vent MRSA from leaking into the subcutaneous soft tis-
sues. A sham operation was undertaken in the control
group. Only the tibia was exposed and no other inter-
vention was taken place. For the PLLA/β-TCP implant-
ation, the tibiae were drilled and no MRSA suspension
was given. The skin and subcutaneous tissues were su-
tured with 2.0 silk (Doğsan, Trabzon, Turkey), and clos-
ure was cleaned and sprayed with an antibacterial film
(Opsite, Smith & Nephew, London, England) [18]. Rats
were put into cages allowing their free movement and
fed with regular diet. Anterior-posterior and lateral ra-
diographs of the tibia were obtained after 3 weeks in the
IRO groups using the Siemens Multix-C (Siemens AG,umber; t = time; IRO = implant-related chronic osteomyelitis.
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and 2.5 mAs/s to confirm radiological signs of IRO es-
tablishment. The distance between the X-ray source and
the samples was 100.0 cm at examination. Agfa Crurix
X-ray films (Agfa, Mortsel, Belgium) and the Crurix 60
(Agfa, Mortsel, Belgium) automatic developing machine
were used. When macroscopic and radiologic signs of
IRO became definite, all closures were reopened and
only one composite implanted into the burr hole was
found in the tibia based on its group. After 1 and
6 weeks, radiographs were obtained and two orthopedic
surgeons who had no prior information of the groups
independently evaluated the radiographs for the pres-
ence of IRO. Radiologic criteria were: (1) periosteal re-
action, (2) diaphyseal widening, (3) osteolysis, (4) bone
deformation, (5) sequestrum formation, (6) joint effu-
sion, and (7) soft tissue swelling. Parameters 1 to 4 were
graded as (0) absent, (1) mild, (2) moderate, and (3) se-
vere, and parameters 5 to 7 were graded as (0) absent
and (1) present [19]. Swab cultures were obtained for
microbiological analysis. A sterile stripe was smeared
into the implantation site to take culture. The stripes
were streaked onto blood agar plates and incubated at
37°C for 12 h and the presence or absence of growth in
the media was recorded. The animals were sacrificed by
lethal doses of anesthetics and tibiae of the left hind leg
were dissected. All soft tissues were removed and bones
were fixed in 10% phosphate buffered formalin (pH 7.0)
at room temperature for histological analysis at termin-
ation. Samples were then decalcified by immersion in
De Castro solution [nitric acid (Merck, Darmstadt,
Germany), chloral hydrate (Merck, Darmstadt, Germany),
and distilled water] for 5–10 days before dehydration.
Tibiae were rinsed in buffer and dehydrated in a graded
series of ethanol before embedding in paraffin in an
automated tissue processor (TP-1020, Leica, Wetzlar,
Germany). For each tibia, we determined the severity of
infection with 60–80 5-μm-thick hematoxylin and eosin
and trichrome-stained serial sections using a DMR 6000
microscope equipped with the DC500 digital camera
(Leica, Wetzlar, Germany). Semi-quantitative image
analysis was undertaken using the Qwin Plus computer
image analysis system (Leica, Wetzlar, Germany). The
medullar cavity (leukocytes, microabscesses, granula-
tion tissue, fibrosis), cortex (destruction of the cortex,
enlarged Haversian canals, leukocytes, microabscesses,
granulation tissue, fibrosis), and periosteal reaction
(quantity) were scored according to the literature [ac-
cording to severity as none, slight, moderate, or much
from 0 to 4] in at least ten regions of interest [20]. The
total score was calculated and noted for the statistical
analysis.
Descriptive values are expressed as the minimum, the
maximum, and the median. As all the scores for thecontrol group were zero, this group was taken off from
statistical analysis. Normality of distribution and homo-
geneity of variances were adjusted using the Shapiro-
Wilk test. Radiological and the histological scores were
analyzed by nonparametric tests (Kruskal-Wallis for
multiple comparison and Mann Whitney U as post hoc
test with Bonferroni correction; p <0.0083 was consid-
ered significant.). Spearman’s test was used to assess cor-
relations between continuous radiology and histology
variables. The Pearson product–moment correlation co-
efficient test was used for the interobserver and intraob-
server reliabilities.
Each author certifies that Hacettepe University Animal
Care and Use Ethics Committee approved (no. 2007/65-
1) the animal protocol for this investigation and that all
investigations were conducted in conformity with ethical
principles of research.
Results
MRSA did not grow in the CV- and V-PLLA/β-TCP
groups at any time. MRSA and Escherichia coli were
isolated from four and two of six, and from three and
three of six tibiae in the PLLA/β-TCP group at week 1
and 6, respectively. Radiological score of the V-PLLA/
β-TCP group improved (p =0.043) at week 6 (Figure 2).
Interobserver and intraobserver reliabilities (r) for the
presence or absence of infection were 0.95 and 0.98, re-
spectively. The radiographic scores correlated with
histological scores at weeks 1 (r =0.896; p <0.05) and 6
(r =0.90; p <0.05). Microbiological and radiological
scores from this in vivo study suggest that IRO was
controlled in the CV- and V-PLLA/β-TCP groups but
not in the PLLA/β-TCP group.
PLLA/β-TCP composites implanted into normal bone
without IRO presented healthy cortical osteons and min-
imal or no periosteal reaction histologically, receiving
better scores than the other groups at week 1 (Figure 3).
PLLA/β-TCP composites with IRO exhibited cortical
bone damage with enlarged Haversian canals and granu-
lation tissue formation. Mononuclear cells infiltrated the
medullary canal in the same group. Broad periosteal re-
action at weeks 1 and 6 were observed in the PLLA/β-
TCP groups with IRO. The CV-PLLA/β-TCP group had
comparatively better (p =0.004) histological scores com-
pared with that of the PLLA/β-TCP group at week 6
(Figure 4).
Discussion
Staphylococcal bacteria have adhesion potential to bio-
materials [21] resulting in chronic osteomyelitis and IRO
[6]. This bone infection can be controlled with local
drug delivery systems. CV- and V-PLLA/β-TCP compos-
ites can be a choice since remission of IRO was achieved
with these implants. This study had some limitations. E.
Figure 2 The descriptive data of radiological scores of the groups are shown for weeks 1 and 6: (minimum, maximum, and median
values). V-PLLA/β-TCP with IRO score recruited and PLLA/β-TCP without IRO score regressed on week 6. Note that p <0.0083 for a-c, b-c, d-e, d-f.
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which indicated surgical site contamination. Complex
bacterial contamination is a frequent state in osteomye-
litis due to the open wounds and/or multiple surgeries
[22]; however, CV- and V-PLLA/β-TCP composites
were able to overcome this complication. In vivo degrad-
ation time and reduction of mechanical strength of ourFigure 3 The descriptive data of histological scores of the groups are
values). PLLA/β-TCP without IRO exhibited better scores than the other gr
better scores compared with that of PLLA/β-TCP with IRO at week 6. Notematerial were not measured, as eradication of MRSA was
our primary aim.
Microbiologic findings revealed control of the infec-
tion in the CV- and V-PLLA/β-TCP groups. Bacteria did
not grow in these groups at any time. Radiological scores
correlated well with histological scores and improvement
was achieved in the CV- and V-PLLA/β-TCP groups.shown for weeks 1 and 6: (minimum, maximum, and median
oups at weeks 1 and 6. V-PLLA/β-TCP and CV-PLLA/β-TCP presented
that p <0.0083 for a-b, a-c, a-d, e-f, e-g, e-h.
Figure 4 Histological images (A-E). PLLA/β-TCP without IRO group had a mild tissue reaction in (A) week 1 with HE (B) and week 6 with MT.
The implant is degrading but still present at 6 weeks. PLLA/β-TCP with IRO group had evident bone damage and granulation tissue formation
with mononuclear cell infiltration and periosteal reaction in (C) week 1 with MT and (D) week 6 with HE, respectively. V-PLLA/β-TCP had better
morphologic features of the bone and marrow in (E) week 1 with HE with the presence of new forming healthy spongy bone. CT connective tissue,
TB trabecular bone, CB compact bone, BM bone marrow, GT granulation tissue, I implant, HE hematoxylin and eosin, MT Masson’s trichrome.
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The radiologic score of the PLLA/β-TCP group without
IRO group deteriorated slightly at week 6 most prob-
ably due to composite degradation [25]. A decrease in
pH owing to PLLA degradation could have caused bone
resorption [26] in this group. Histological findings of
the CV- and V-PLLA/β-TCP groups presented favor-
able biocompatibility. TCP is an osteoconductive ma-
terial [27] and influences bone ingrowth in the pores of
the composite. This finding was in line with another
study [16] that demonstrated new trabecular bone for-
mation at the defect margins in biodegradable TCP
composites. Quantitative histology revealed biocom-
patibility and osteointegration as in another study [28].Conclusion
In conclusion, vancomycin-containing PLLA/β-TCP com-
posites presented favorable radiological, histological, and
microbiological results of remission and according to clin-
ical relevance of the study, they can be used to control
IRO in the near future.
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